PT - JOURNAL ARTICLE AU - Baur, Katharina AU - Heim, Dominik AU - Beerlage, Astrid AU - Poerings, Anna S AU - Kopp, Bastian AU - Medinger, Michael AU - Dirks, Jan C AU - Passweg, Jakob R AU - Holbro, Andreas TI - Dasatinib for treatment of CAR T-cell therapy-related complications AID - 10.1136/jitc-2022-005956 DP - 2022 Dec 01 TA - Journal for ImmunoTherapy of Cancer PG - e005956 VI - 10 IP - 12 4099 - http://jitc.bmj.com/content/10/12/e005956.short 4100 - http://jitc.bmj.com/content/10/12/e005956.full SO - J Immunother Cancer2022 Dec 01; 10 AB - Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by proliferating and activated CAR T-cells. Current mainstay treatment includes interleukin-1 and interleukin-6 (IL-6) blockade and steroids. The use of steroids is still controversial, since they may have the potential to irreversibly damage CAR T-cells and thus increase the risk of relapse. Therefore, additional treatment options need to be explored. We report the successful treatment of a patient with a grade 3 CRS and grade 4 ICANS refractory to IL-6 blockade and steroids with the tyrosine kinase inhibitor dasatinib. The use of dasatinib for treatment of CAR T-cell therapy-related severe complications warrants further studies.